Benedict Maliakkal, MD
Gastroenterology · Memphis, TNNPI 1306872155
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,200 of the $19,210 with a category attached, or 84.3%. AbbVie accounts for 73.3% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $8,974 and has fallen 92.0% since, to $719 in 2025. Among gastroenterology clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 68 payments — averaging $282.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$14K
- Intercept Pharmaceuticals, Inc.$3K
- Gilead$617
- Johnson & Johnson$532
- Madrigal Pharmaceuticals$458
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$192
- plus $616 from 10 others
Across 66 payments — averaging $4033.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$92K
- Gilead$78K
- Intercept Pharmaceuticals, Inc.$58K
- Dova Pharmaceuticals$30K
- Bayer$8K
- Merck$198
- plus $159 from 1 others
What the payments were for
- Speaking & faculty fees$16,20084%
- Food & beverage$2,99816%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $14,075 |
| Intercept Pharmaceuticals, Inc. | 4 | $2,720 |
| Gilead | 8 | $617 |
| Johnson & Johnson | 12 | $532 |
| Madrigal Pharmaceuticals | 7 | $458 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $192 |
| Novo Nordisk | 3 | $121 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $118 |
| E.r. Squibb & Sons, L.L.C. | 1 | $104 |
| Ardelyx, Inc. | 2 | $88 |
| Abbott | 3 | $78 |
| Grifols Shared Services North America, Inc. | 1 | $51 |
| Antares Pharma, Inc. | 1 | $17 |
| Cook Medical LLC | 2 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,210 in reported general payments places this provider in the 90th percentile of 336 gastroenterology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 33 | $106,350 |
| JardianceEmpagliflozin | 22 | $28,054 |
| OzempicSemaglutide | 15 | $15,081 |
| LinzessLinaclotide | 13 | $10,370 |
| EliquisApixaban | 12 | $7,780 |
| Tacrolimus | 16 | $1,279 |
| Spironolactone | 36 | $723 |
| Metformin Hcl ErMetformin Hcl | 19 | $481 |
| Pantoprazole Sodium | 30 | $415 |
| Carvedilol | 38 | $360 |
| Celecoxib | 11 | $154 |
| Furosemide | 14 | $92 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $192 | $106,35033 claims |
| Novo NordiskOzempic | $121 | $15,08115 claims |
| AbbVieLinzess | $14,075 | $10,37013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 336 gastroenterology providers in Tennessee.
Other gastroenterology in Memphis
- Satheesh NairMemphis$349K
- Colin HowdenMemphis$291K
- Leonard BaidooMemphis$152K
- Sanjaya SatapathyMemphis$16K
- Kenneth FieldsMemphis$11K
- Randelon SmithMemphis$10K
- David SchwartzNashville$1.3M
- Ziad YounesGermantown$1M
- Dawn Borromeo BeaulieuNashville$421K
- Sara HorstNashville$246K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.